PBAC's latest decision on Venetoclax: Recommended with restriction (2021). Considered for Treatment of newly diagnosed acute myeloid leukaemia (AML) in adults ineligible for standard intensive remission induction chemotherapy, in combination with azacitidine.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$95k/QALY
$75k/QALY–$95k/QALY · across 3 submissions
Submissions
8
first 2017
PBS spend
$74M
12,115 scripts · 2024
Eligible population
Adults with newly diagnosed acute myeloid leukaemia ineligible for standard intensive induction chemotherapy.
Range aggregates 3 submissions (2017–2021) — not a single base case.
Risk sharing
Risk-sharing arrangement in place — Risk-sharing arrangement proposed consisting of financial caps based on estimated net PBS/RPBS cost for venetoclax and a rebate for use beyond annual caps.
PBS expenditure
The Australian government paid $74M in PBS benefits for Venetoclax in 2024 across 12,115 scripts, at $6,118 per script.
Submission history
Mar 2017: Recommended with restriction · Authority Required